sales@dcchemicals.com
113-O12B
Formulation & Performance
Literature-reported formulation composition
| Component | mol% | Role |
|---|---|---|
| 113-O12B | Not reported | Ionizable lipid |
| Cholesterol | Not reported | Sterol |
| DOPC | Not reported | helper_lipid |
| DMG-PEG2000 | Not reported | PEG lipid |
| Reported total | Not reported | Source values retained |
Formulation calculator unavailable. The supplied article does not report the complete molar composition, so a formulation weight calculation is not available. Obtain and verify the complete composition and component molecular weights before planning component quantities.
Literature-reported performance for the cited formulation
Literature-reported113-O12B showed higher LN and lower liver expression than ALC-0315 after SC dosing; ALC-0315 liver radiance was about fourfold higher than LN radiance, whereas 113-O12B liver signal was 32% of LN signal.mLuc LNP, 6 h after SC injectionPrimary article Fig. 1D-E
Literature-reportedApproximately 27% of dendritic cells and 34% of macrophages were positive after 113-O12B/mCre, both higher than ALC-0315 in the same experiment.Ai14 mice, 48 h after SC mCrePrimary article Fig. 1F-G
Literature-reported113-O12B/mOVA vaccination prevented obvious B16F10-OVA tumor growth and prevented apparent lung metastatic nodules in the reported rechallenge experiment.Two vaccinations; 50 µg active lipid + 5 µg mOVA per dosePrimary article Fig. 2
Literature-reported113-O12B/mOVA prolonged survival; anti-PD-1 combination increased complete response to 2/5 mice in the reported experiment.Established tumor; vaccine days 5 and 12; anti-PD-1 days 7, 11 and 15Primary article Fig. 4
Literature-reported113-O12B/mTRP2 plus anti-PD-1 achieved a 40% complete-response rate and surviving complete responders showed no metastatic lung nodules on rechallenge.30 µg active lipid + 3 µg TRP2 mRNA per dosePrimary article Fig. 5 and Discussion
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetChen J, Ye Z, Huang C, et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response. Proc Natl Acad Sci USA. 2022;119:e2207841119.
Formulation and performance source locations are listed with the evidence items above.
Formulation and performance source locations are listed with the evidence items above.